Isosorbide ( DrugBank: Isosorbide )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 2 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-004427-37-IT (EUCTR) | 01/10/2014 | 04/09/2014 | Efficacy and tolerability of ibuprofen and isosorbide dinitrate (20 mg, 40 mg, 60 mg, 80 mg) | Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid) and Isosorbide Dinitrate (20 mg, 40 mg, 60 mg, 80 mg) - ESPP001 | Restrictive respiratory syndrome with frequent pulmonary infections and cardiomyopathy.wasting of skeletal muscle, severe local inflammation and, at least initially, muscle regeneration. MedDRA version: 17.0;Level: PT;Classification code 10064571;Term: Gene mutation;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Trade Name: Isosorbide Dinitrate 20 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: IBUPROFEN 200MG INN or Proposed INN: IBUPROFEN Trade Name: Isosorbide Dinitrate 40 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: Isosorbide Dinitrate 60 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: Isosorbide Dinitrate 80 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE | PARENT PROJECT ONLUS | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 188 | Italy | |||
| 2 | NCT01478022 (ClinicalTrials.gov) | October 2011 | 14/11/2011 | To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 | Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses | Duchenne Muscular Dystrophy (DMD) | Drug: Isosorbide Dinitrate;Drug: Ibuprofen;Other: Ibuprofen and Isosorbide Dinitrate combination | Parent Project, Italy | NULL | Completed | 18 Years | 27 Years | All | 12 | Phase 1 | Italy |